President Donald Trump has nominated Dr. Erica Schwartz to lead the CDC, continuing a series of leadership changes at the U.S. public health agency.
 |
| Dr. Erica Schwartz has been nominated to lead the U.S. Centers for Disease Control and Prevention. |
WASHINGTON – President Donald Trump has announced the nomination of Dr. Erica Schwartz as the next director of the Centers for Disease Control and Prevention (CDC), further reshaping the leadership of the federal health agency.
The announcement was made via Truth Social, where Trump praised Schwartz’s medical background and leadership experience in public health and military service.
A New Leadership Choice for the CDC
If confirmed by the Senate, Dr. Schwartz would take over an agency that has experienced multiple leadership changes in recent years.
She previously served as a deputy surgeon general and held senior medical roles within the U.S. Navy and Public Health Service Commissioned Corps.
Political Backdrop and Agency Instability
The CDC has seen significant leadership turnover since mid-2025, with multiple directors serving short terms amid internal disputes over public health policy and vaccine guidance.
Schwartz would become the fourth individual nominated or appointed to lead the agency since last summer, highlighting ongoing instability within the organization.
Previous Controversies at the CDC
Recent leadership changes at the CDC have been marked by disagreements over vaccine policy and scientific decision-making, leading to Senate hearings and public disputes among senior health officials.
Some former officials have claimed they were removed for resisting political pressure, while others have disputed those accounts during congressional testimony.
Key Highlights
- Dr. Erica Schwartz nominated as new CDC director
- Announcement made by President Trump on Truth Social
- Schwartz is a former deputy surgeon general and Navy medical officer
- Fourth CDC leadership change since mid-2025
- Nomination awaits Senate confirmation
What Happens Next?
The U.S. Senate will now review Schwartz’s nomination, which could determine the next phase of leadership at the CDC.
The decision comes at a time of heightened scrutiny over public health policy and federal agency governance.
What do you think?
Should federal health agencies prioritize stability or frequent leadership changes to improve accountability? Share your opinion below.